# EDGAR Filing Document

**Accession Number:** 0001536196
**File Stem:** 0001213900-23-013677
**Filing Date:** 2023-2
**Character Count:** 2622
**Document Hash:** abc89b495db723345777b016183ced15
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-013677.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001213900-23-013677

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230222

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Can-Fite BioPharma Ltd.
- **CENTRAL INDEX KEY:** 0001536196
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36203
- **FILM NUMBER:** 23653281

**BUSINESS ADDRESS:**
- **STREET 1:** 10 BAREKET STREET, KIRYAT MATALON
- **STREET 2:** P.O. BOX 7537
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4951778
- **BUSINESS PHONE:** 972 39241114

**MAIL ADDRESS:**
- **STREET 1:** 10 BAREKET STREET, KIRYAT MATALON
- **STREET 2:** P.O. BOX 7537
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4951778

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of February 2023

001-36203

(Commission File Number)

**CAN-FITE BIOPHARMA LTD.**

(Exact name of Registrant as specified in its charter)

**10 Bareket Street**

**Kiryat Matalon, P.O. Box 7537**

**Petach-Tikva 4951778, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On February 22, 2023, a Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the "Company") approved each of the two proposals brought before the Company's shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company's Notice and Proxy Statement with respect to the Company's Special General Meeting of Shareholders, dated January 13, 2023, attached as Exhibit 99.1 to the Company's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on January 13, 2023.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 22, 2023 | By: | /s/ Pnina Fishman |
|  |  | Pnina Fishman |
|  |  | Chief Executive Officer |

---